Skip to primary content

Skip to secondary content

Biotech 365

Search

Main menu

Biotech 365
Companies
Healthcare Investors
- Healthcare LPs
Preclinical Studies Database
- CRO & CDMO Marketplace
- Scientific Due Diligence
Free DEMO
Services
Contact

Tag Archives: autologous adoptive immunotherapies

Cellectis – gene-editing

Posted on by

Cellectis is a biotech company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).

Cellectis – gene-editing

Continue reading →

Posted in Biotech Companies, Biotech Companies France | Tagged Acute lymphoblastic leukemia, Acute myeloid leukemia, adoptive immunotherapies, adoptive immunotherapy, Alain Godard, ALCLS, ALL, allogeneic T cells engineered, AML, André Choulika, Annick Schwebig, autologous adoptive immunotherapies, autologous adoptive immunotherapy, B cells malignancies, CAR, CAR-engineered cell, Cellectis, Cellectis - gene-editing, Chimeric Antigen Receptor, Chronic lymphocytic leukemia, CLL, David Sourdive, electroporation PulseAgile technology, engineered nuclease, engineered nucleases, gene edited engineered CAR-T cell, gene edited engineered CAR-T cells, gene edited engineered T cell, gene engineering, gene-editing, genome engineering, glioblastoma, immunotherapies, immunotherapy, Laurent Arthaud, leukemia, Mathieu Simon, meganuclease, meganucleases, Multiple myeloma, non-small-cell lung cancer, pancreatic cancer, Philippe Duchateau, Pierre Bastid, PulseAgile, T cells, T-cell, TALEN, TALEN products, Thierry Moulin, UCART

Search

Services Healthcare Investors Database FAQs CGU Biotech & Pharma News Contact

Proudly powered by WordPress